Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ) SHZ

Currency In CNY

AD

Valuation

Market Cap4.4B
Enterprise Value3.95B
P/E Ratio147.78
PEG Ratio-3.08
Price/Sales Ratio7.72
Price/Book Ratio2.25
Enterprise/Revenue6.8
Enterprise/EBITDA46.31

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin0.07
Operating Margin-0
AD

Management Effectiveness

Return On Assets0.01
Return On Equity0.01

Income Statement

Revenue453.31M
Revenue/Share1.1
Gross Profit100.2M
EBITDA84.81M
Net Income34.91M
Diluted EPS0.1

Balance Sheet

Total Cash1.54B
Total Cash/Share3.69
Total Debt2.35M
Total Debt/Equity0
Current Ratio17.18
Book Value Per Share5.47

Price History

52-Week Change-2.15
52-Week High16.95
52-Week Low9.01
Moving Average 50 Days10.76
Moving Average 200 Days12.35

Statistics

Average Volume7.28M
Shares Outstanding288M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0.06
Trailing Annual Dividend Yield0.49
Payout Ratio2.13
Last Split Factor29:20
Last Split DateAugust 27, 2025
AD